Feb 13
7:00PM – 8:00PM
ET
Add to Calendar
2025-02-13T19:00:00
2025-02-13T20:00:00
America/New_York
Yale Career Panels: A Candid View of the Biotech Profession
Yale Career Panels
A Candid View of the Biotech Profession
February 13, 2025
7:00 pm ET
This event is the 65th in a series of events covering different professions and career issues. There have been 54 Yale Career Panels, 9 Yale Career Fireside Chats, 1 Advisor and Networking event and 1 Yale Career Conversations event. Organized 14 years ago by a group of Yale alumni volunteers, these panels strive to provide candid, unvarnished views of featured professions.
Biotech is an important industry that has been responsible for the invention and thousands of new drugs, vaccines, and novel treatments for many diseases. It has become an important source of new products that are either approved and commercialized by the biotech company or by larger pharmaceutical companies. The vaccine to prevent Covid-19 is one example of the success of the biotech industry. There are many different career paths in biotech that one can pursue.
We have assembled a panel that has the experience to comment on careers in the biotech industry in a comprehensive and candid manner that will be helpful if you are contemplating a career in biotech.
The panel discussion will be broadcast via streaming video.
The volunteer organizers of the Yale Career Panels are Daisy Du, Justin Kosslyn, Zahid Lahani, Vivian Lin, Julie Sohn, Gale Spak, Trish Takemoto, Grace Young, and Peter Young. This panel was organized by Daisy Du.
Date: Thursday, February 13, 2025
Time: 7:00 pm to 8:00 pm ET
Registration: http://yalecareerpanels-2-13-25.eventbrite.com
• Where is profession heading (good and bad)?
• How do you get into the profession and what is the typical career path?
• What are the myths versus the realities?
• What are the characteristics of people who tend to do well and are happy in the profession?
• What types of people tend not to do well or end up unhappy and why?
• If you don’t stay in the profession until retirement, what are the exit routes to other professions?
• What is your advice for people who are thinking about entering this space?
Panelists:
Peikwen Cheng: Co-Founder and CEO of Yiviva (Stanford University (B.Sc., Engineering - Product Design), INSEAD and Tsinghua University (dual Executive MBA)
Linda Grais, MD, JD: Lecturer in Management, Stanford Business School, former CEO of Ocera Therapeutics, Inc., and former Partner of Interwest Partners, (Yale B.A. in Philosophy, Yale Medical School M.D., Stanford Law School J.D.)
Moderator:
Peter Young, CEO of Young & Partners (Yale B.A., NYU M.S. in Accounting, Harvard Business School MBA)
Panelist Biographies
Peikwen Cheng
Co-Founder and CEO of Yiviva
Peikwen Cheng is a Co-Founder and CEO of Yiviva - a clinical-stage, platform biotech spun out of Henry Bronson Professor of Pharmacology Yung-Chi Cheng’s laboratory at Yale University. Yiviva is developing multi-targeted medicines using a systems biology approach to improve cancer patient survival and quality of life. Their work has been recognized with an Innovation Award at the US-China Health Summit and has been featured in National Geographic’s “Future of Medicine” about how “New Technologies and Ancient Remedies are Transforming Healthcare”.
Peikwen is a founding Co-President of Stanford Alumni in Healthcare, and has been a fellow at NewYorkBIO and Yale’s Venture Creation Program, and member of the Alumni Steering Committee of New York City Economic Development Corporation’s Bio and Health Tech Entrepreneurship Lab. He is a graduate of Stanford University (B.Sc., Engineering - Product Design), INSEAD and Tsinghua University (dual Executive MBA) and trained as an Emergency Medical Technician at the Wilderness Medicine Institute.
Linda Grais
Lecturer in Management, Stanford Business School, former CEO of Ocera Therapeutics, Inc., and former Partner of Interwest Partners
Linda Grais, M.D., J.D., has broad experience in healthcare as a physician, entrepreneur, biopharma CEO and board member. Dr. Grias was President, Chief Executive Officer and member of the Board of Directors of Ocera Therapeutics, a biopharmaceutical company developing novel treatments for gastrointestinal and liver diseases, from 2012 until its acquisition in 2017. Previously, she was a Partner of InterWest Partners, a venture capital firm investing in drug development and medical device companies. Dr. Grais was a founder and executive vice president of Structural GenomiX, which pioneered the use of genomics and proteomics to accelerate drug discovery, went public and was acquired by Eli Lilly. Dr. Grais trained in Internal Medicine and Critical Care Medicine at the University of California, San Francisco, where she was an Assistant Clinical Professor.
Dr. Gris received an B.A. from Yale University, Magna Cum Laude and Phi Beta Kappa, and M.D. from Yale Medical School, and a J.D. from Stanford Law School. Dr. Grais is currently a Lecturer in Management at the Stanford Graduate School of Business and a board member of several companies developing new therapeutics, including ICON plc (NASDAQ: ICLR), a leading CRO, Corvus Pharmaceuticals (NASDAQ: CRVS), Iolyx Therapeutics and Collective Health.
Moderator’s Biography
Peter Young (Moderator)
CEO of Young & Partners
Peter Young is President and a Managing Director of Young & Partners, a leading boutique investment banking firm focused on the life science and chemical industries. He manages the firm and is actively involved in client transactions and financings. Under his leadership, Young & Partners has established and maintained its position as a highly regarded firm.
Prior to founding Young & Partners, Peter was head of various related industry groups at Salomon Brothers, Schroders, and Lehman Brothers for ten years. Peter has been an investment banker serving the chemical and pharma industries for twenty seven years, assisting a wide variety of chemical and life science companies on a global basis with regard to mergers, acquisitions, restructurings and capital raising.
Early in his career, while with Bain & Co., Peter provided strategic advice to major chemical and life science companies. He was also a senior member of J.H. Whitney & Co. the venture capital firm.
false